No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes. a randomized, double-blind, placebo-controlled trial by Barchetta, Ilaria et al.
RESEARCH ARTICLE Open Access
No effects of oral vitamin D
supplementation on non-alcoholic fatty
liver disease in patients with type 2
diabetes: a randomized, double-blind,
placebo-controlled trial
Ilaria Barchetta1, Maria Del Ben1, Francesco Angelico1, Michele Di Martino2, Antonio Fraioli1, Giuseppe La Torre3,
Rosella Saulle3, Ludovica Perri1, Sergio Morini4, Claudio Tiberti5, Laura Bertoccini5, Flavia Agata Cimini1,
Francesca Panimolle5, Carlo Catalano2, Marco Giorgio Baroni5,6 and Maria Gisella Cavallo1*
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder worldwide, reaching
prevalence up to 90 % in obese patients with type 2 diabetes (T2D), and representing an independent risk factor
for cardiovascular mortality. Furthermore, the coexistence of T2D and NAFLD leads to higher incidence of diabetes’
complications and additive detrimental liver outcomes. The existence of a close association between NAFLD and
hypovitaminosis D, along with the anti-inflammatory and insulin-sensitizing properties of vitamin D, have been
largely described, but vitamin D effects on hepatic fat content have never been tested in a randomized controlled
trial. We assessed the efficacy and safety of 24-week oral high-dose vitamin D supplementation in T2D patients
with NAFLD.
Methods: This randomized, double-blind, placebo-controlled trial was carried out at the Diabetes Centre of
Sapienza University, Rome, Italy, to assess oral treatment with cholecalciferol (2000 IU/day) or placebo in T2D
patients with NAFLD. The primary endpoint was reduction of hepatic fat fraction (HFF) measured by magnetic
resonance; as hepatic outcomes, we also investigated changes in serum transaminases, CK18-M30, N-terminal
Procollagen III Propeptide (P3NP) levels, and Fatty Liver Index (FLI). Secondary endpoints were improvement in
metabolic (fasting glycaemia, HbA1c, lipids, HOMA-IR, HOMA-β, ADIPO-IR, body fat distribution) and cardiovascular
(ankle-brachial index, intima-media thickness, flow-mediated dilatation) parameters from baseline to end of treatment.
Results: Sixty-five patients were randomized, 26 (cholecalciferol) and 29 (placebo) subjects completed the study.
25(OH) vitamin D significantly increased in the active treated group (48.15 ± 23.7 to 89.80 ± 23.6 nmol/L, P < 0.001);
however, no group differences were found in HFF, transaminases, CK18-M30, P3NP levels or FLI after 24 weeks. Vitamin
D neither changed the metabolic profile nor the cardiovascular parameters.
Conclusions: Oral high-dose vitamin D supplementation over 24 weeks did not improve hepatic steatosis or
metabolic/cardiovascular parameters in T2D patients with NAFLD. Studies with a longer intervention period are
warranted for exploring the effect of long time exposure to vitamin D.
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Background
Non-alcoholic fatty liver disease (NAFLD) is the most
common cause of liver disease worldwide [1], with an
estimated prevalence of 20 % in the general population
and up to 90 % in obese patients affected by type 2 dia-
betes (T2D) [2, 3]. Diabetes itself, in turn, is capable of
accelerating the evolution from NAFLD to non-alcoholic
steatohepatitis (NASH), severe fibrosis, cirrhosis and
hepatocarcinoma, increasing the liver-related mortality
risk [4–7]. Conversely, the presence of NAFLD in T2D
patients is associated with worse metabolic profile, greater
insulin resistance and higher rate of diabetes’ micro- and
macro-vascular complications [8–12]. Indeed, NAFLD is
now considered an independent risk factor for cardiovas-
cular mortality [13].
Although several nutraceutical and pharmacological
interventions for NAFLD have been proposed, none has
shown significant results in an adequate experimental
setting, so that NAFLD therapy still remains an open
issue [14]. At present, there is no medically approved
treatment for NAFLD and a wide variety of nutraceuti-
cals with several modes of action are currently under
clinical evaluation.
Contextually to the large evidence on a relationship
between low vitamin D levels and metabolic diseases
[15–17], an independent correlation between hypovita-
minosis D and NAFLD has been reported. In particular,
low vitamin D levels have been associated with the histo-
logical severity of NAFLD/NASH [18] and with the
prevalence of NAFLD among individuals with normal
liver enzymes [19]. Overall, a 26 % additional risk for
vitamin D deficiency has been reported in NAFLD sub-
jects compared to controls in the only meta-analysis
available [20]. A strong epidemiological overlap also ex-
ists between NAFLD and hypovitaminosis D prevalence,
as both conditions are widely spread among obese dys-
metabolic individuals [17, 21]. Vitamin D exerts a direct
action on the liver through its specific receptor, VDR,
expressed in all hepatic cell populations; notably, its expres-
sion negatively correlates with the inflammatory damage in
chronic hepatic diseases [22]. Experimental data showed an
overall insulin-sensitizing effect of vitamin D via free fatty
acids (FFAs) flux modulation and GLUT-4 muscular ex-
pression [23], along with its anti-inflammatory, anti-
proliferative and anti-fibrotic activities in the liver [24, 25].
Moreover, vitamin D supplementation has been recently
demonstrated to reduce the hepatic levels of cytokeratin 18
apoptotic fragment M30 (CK18-M30), a marker of hepatic
damage hugely validated in NAFLD/NASH [26, 27] and in
rats affected by NASH [28].
Very recently, a prospective small pilot study evaluated
the impact of 24-week high-dose oral vitamin D supple-
mentation on liver histology of 12 non-cirrhotic NASH
patients, finding no beneficial effects of this treatment
on hepatic damage or insulin sensitivity [29]; however,
vitamin D effects on hepatic fat content in NAFLD have
never been tested. Therefore, the aim of the present
study was to assess the efficacy and safety of 24-week oral
high-dose vitamin D supplementation in T2D patients af-
fected by NAFLD, specifically assessing hepatic fat.
Methods
Role of the funding source
Authors had full access to the trial data. Funders had no
role in study design, data collection, analysis, interpretation
and decision to publish study findings.
Study design and participants
This is a monocentric, randomized, double-blind, placebo-
controlled trial. Study participants were recruited among
patients referring to the Diabetes outpatients’ clinic of
Sapienza University of Rome, Italy, for diabetes care. Be-
tween March 2012 and September 2014, 65 patients were
randomized. To be eligible for the study, patients had to
satisfy the following criteria: male or female subjects be-
tween 25 and 70 years of age; diagnosis of T2D according
to ADA 2009 criteria [30]; presence of fatty liver detected
by upper abdominal ultrasound echography (US) and con-
firmed by magnetic resonance (MRI) in subjects with a
clinical suspect of NAFLD (increased serum transaminase
levels in absence of known hepatic chronic disease,
alanine aminotransferase (ALT) > aspartate aminotransferase
(AST), presence of multiple components of metabolic
syndrome); negative tests for the presence of hepatitis
B surface antigen and antibody to hepatitis C virus. The
main exclusion criteria from the study were as follows:
history of alcohol abuse (as defined by an average daily
consumption of alcohol > 30 g/day in men and > 20 g/day
in women), cirrhosis, autoimmune hepatitis and other
causes of liver disease (hemochromatosis, Wilson’s
disease), chronic enteropathies, advanced renal failure,
cancer, hyper/hypoparathyroidism, known hypersensitivity
to cholecalciferol or any other excipients, hypercalcemia,
hypercalciuria, nephrolithiasis, nephrocalcinosis, ongoing/
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recent (previous 6 months) supplementation with vitamin
D, calcium, multivitamin products, treatment with
agents affecting bone and calcium/vitamin D metabol-
ism (anticonvulsants, glucocorticoids, antacids contain-
ing aluminum, cholestyramine), UV radiation exposure,
pregnancy and lactation, or severe psychiatric illnesses.
Ethics, consent and permissions
This clinical trial was conducted in accordance with
Good Clinical Practice guidelines, and was registered at
www.clinicaltrialsregister.eu (number 2011-003010-17).
The study protocol was reviewed and approved by the
Ethics Committee of Policlinico Umberto I, Sapienza
University of Rome and the study was conducted in con-
formance with the Helsinki Declaration. Written consent
was obtained from all patients before the study. The ori-
ginal protocol for the clinical trial (Additional file 1) and
the supporting CONSORT checklist (Additional file 2)
are provided as supporting information.
Randomization and masking
Randomization was performed by the statistician following
acquisition of participants’ informed consent, through a
computer-generated and centrally administered procedure.
Patients were randomized 1:1 according to the method of
block randomization with a block size of 5. Treatment
(cholecalciferol, 25.000 IU/2.5 mL) and placebo were pro-
vided in identical vials by an experienced independent
pharmacist (Dr. Baiocco E, Rome, Italy); the recommended
intake was eight drops a day, equivalent to cholecalciferol
2000 IU/day in the active-treated group, for duration of
the study (24 weeks). Patients, investigators, clinical site
staff, laboratory staff and radiologists were all masked to
treatment assignment throughout the study. Participants
were asked to return the drug vials when attending the
follow-up visits in order to assess their compliance to
study treatment.
Procedures
After randomization, patients underwent the baseline
visit and received the first supply of study medication, as
required for 12 weeks. The first follow-up visit took
place after 12 weeks and treatment continued for a fur-
ther 12 weeks; returned vials were checked and collected
and then new supplies were provided as required for the
last 12 weeks of treatment.
At the baseline, 12- and 24-week visits, study partici-
pants underwent a complete work-up including clinical
examination, anthropometric measurements and labora-
tory tests. All medications were carefully recorded at
baseline visits and drug alterations regarding antidiabetic
agents, anti-hypertensive treatments and statins were
not allowed throughout the study.
Weight and height were measured with patients wear-
ing light clothing and no shoes. The body mass index
(BMI) was calculated as weight in kilograms divided by
the square of the height in meters. Waist circumference
was measured midway between the 12th rib and the iliac
crest. Blood pressure [systolic (SBP) and diastolic (DBP)]
was measured after 5 minutes of rest using an electronic
auscultatory blood pressure recorder with an appropriately
sized cuff based on the measurement of arm circumfer-
ence with the patient sitting in the upright position. Three
measurements were taken and the average of the second
and third measurements was recorded and used in the
analyses.
Fasting glycaemia (FBG), glycosylated hemoglobin
(HbA1c), total cholesterol, high-density lipoprotein chol-
esterol (HDL), triglycerides, AST, ALT, gamma-glutamyl
transpeptidase (γ-GT) and C-reactive protein (CRP)
were measured by standard laboratory methods. Fasting
blood insulin (FBI) was assessed by radio-immuno-assay
(PANTEC s.r.l., Italy; intra- and inter-assay coefficients
of variation < 5 %). Serum FFAs were measured by
standard colorimetric methods and circulating adiponec-
tin levels by enzyme-linked immunosorbent assay (Tema
Ricerca s.r.l., Italy; intra- and inter-assay coefficients of
variation = 5 %). As non-invasive biomarkers of hepatic
damage and fibrosis, we measured serum CK18-M30
concentrations by Human Cytokeratin 18-M30 ELISA
kit (Cusabio®, intra- and inter-assay coefficients of vari-
ation < 8 %) and circulating N-terminal Procollagen III
Propeptide (P3NP) levels [31] by Human PIIINP ELISA
kit, Elabscience™ (intra- and inter-assay coefficients of
variation < 10 %). Serum 25(OH) vitamin D concentration
(25(OH)D) was measured as an indicator of vitamin D sta-
tus [32] by a validated colorimetric method (LAISON,
DiaSorin) and then adjusted on the basis of the sampling
period, as described elsewhere [33]. Low-density lipopro-
tein cholesterol (LDL) values were calculated using the
Friedewald formula. The homeostasis model assessment
of insulin resistance (HOMA-IR) and insulin secretion
(HOMA-β%) and the quantitative insulin sensitivity check
index (QUICKI) were calculated as previously described
[34]; the adipose tissue (AT) insulin-resistance was quanti-
fied by the ADIPO-IR index [35]. Fatty Liver Index (FLI)
was used as a clinical correlate of NAFLD [36]. Liver US
scanning was performed to assess the presence of hepatic
steatosis by an Esaote Medica apparatus equipped with a
convex 3.5 MHz probe.
All MRIs were performed by the same operator, unaware
of treatment group and blinded to laboratory values, at the
screening visit and within two weeks from the 24-week
visit, using a 1.5-T magnet (Magnetom Avanto, Siemens
Medical Systems, Erlangen, Germany) equipped with a
phased-array surface coil and a spine array coil. Image
acquisition was performed in the axial plane during an
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end-expiratory breath-hold using a sensitivity encoding
(SENSE) technique in order to reduce the overall acquisi-
tion time to approximately 15 sec. The hepatic fat fraction
(HFF) was obtained by using a two-dimensional spoiled
GRE acquired on the axial plane. To minimize T1 effects,
a low flip angle (10°) was used at a repetition time of
150 msec. To estimate fat-water signal interference and
T2* effects, three echoes were obtained at serial opposed-
phase (OP) and in-phase (IP) echo times (2.3, 4.7,
6.9 msec). Other parameters applied were: section thick-
ness (5 mm), matrix size (256 × 182) and field of view
(35 × 40 cm) [37]. HFF was calculated from the mean of
the two in-phase sequences (IP correct) subtracted to the
out-of-phase sequence and then divided to the “2* IP cor-
rect” sequence. Eight different ROIs measuring 2 cm2
were drawn, one for each hepatic segment within the liver,
avoiding areas with vessels, motion artifacts and partial
volume effects; ROIs were placed at anatomically matched
locations on paired images by using a co-registration tool
available on the picture archiving and communication sys-
tem workstation. Finally, mean ± SD HFF was calculated
for each patient. For visceral and subcutaneous adipose
tissue area quantification (VAT, SAT; cm2) a 3D GRE T1-
weighted VIBE sequence on axial plane modified by
DIXON was acquired (TR, 4.7 msec; TE, 2.3 msec; flip-
angle, 10 °C; matrix, 256 × 192 mm; section thickness,
5 mm, reconstructed 2.5 mm; intersection gap, 0). The
fat-only datasets were transferred to personal computers
for the analysis using a commercially available software
(Slice-O-Matic; Tomovision Inc., Montreal, Canada) and
data were calculated from AT area at L1-L2, L2-L3, L3-L4
and L4-L5 levels; a free-form ROI and manual thresh-
old were used to select fat tissue within VAT and SAT
slides. Means ± SD basal and 24-week VAT and SAT
areas were then calculated in each patient for statistical
purposes.
The cardiovascular evaluation was carried out at the
baseline and 24-week visit. Carotid longitudinal ultrasound
was performed to measure the intima-media thickness
(IMT) of both sides, 1 cm proximally to the carotid bulb.
Three IMT measurements were obtained and then the
mean was calculated; the average value between right
and left IMT was used for the statistical analyses. US
assessment of endothelial dependent and independent
flow-mediated dilatation (FMD) of brachial artery was
investigated by a 7.5-MHz linear array transducer ultra-
sound system (Siemens) equipped with electronic calipers,
vascular software for two-dimensional imaging, color and
spectral Doppler, and internal electrocardiogram; FMD was
expressed as a change in post-stimulus diameter (percent-
age of the baseline diameter). The ankle-brachial index
(ABI) was calculated as the ratio of ankle and brachial SBP
measured separately for the right and left sides, then an
average value was calculated for statistical purposes.
Primary and secondary outcomes
The primary outcome was the reduction of MRI-
measured HFF from baseline to 24 weeks. As additional
indicators of hepatic injury in NAFLD we considered
the changes in transaminases, CK18-M30, P3NP levels
and FLI from baseline to 24 weeks. Secondary outcomes
were the metabolic profile’s improvement, as assessed by
changes in FBG, FBI, HbA1C, total, HDL and LDL choles-
terol, triglycerides, FFAs, HOMA-IR, QUICKI, ADIPO-IR,
HOMA-β and body fat distribution (VAT and SAT areas),
and the modification of endothelial-cardiovascular param-
eters SBP, DBP, ABI, IMT, FMD and circulating CRP levels
from baseline to the end of the study. Adverse events were
recorded at each visit.
Statistical analysis
This is the first randomized controlled trial aiming to in-
vestigate the effect of oral vitamin D supplementation
on NAFLD. Considering a treated/controls ratio of 1:1,
an estimated HFF reduction of 50 % in the active treated
group and of 10 % in the placebo group, together with a
drop-out rate of 10 %, we needed to enroll 24 + 10 % =
27 patients in each group, with a power of 80 % and a
sensitivity of 95 %. Differences between the treated and
control groups were evaluated by non-parametric tests.
Linear regression analyses, adjusted for baseline values,
were performed to assess the mean difference between
the intervention and the placebo groups after 24 weeks
(mean difference is reported as β, along with the 95 %
confidence interval); SPSS version 23 was used to per-
form all the analyses.
Results
Of the 74 patients screened for eligibility, 65 met the in-
clusion criteria and were recruited in our study. Of
these, 36 were allocated to group A (placebo) and 29 to
group B (cholecalciferol 2000 IU/day); in total, 84.6 % of
study population (n = 29 in placebo and n = 26 in treat-
ment group) completed the study (Fig. 1). Four patients
withdrew their informed consent before study conclu-
sion and four patients were lost at follow-up. As per the
safety profile, no major adverse events occurred during
the study, one patient in the treatment group referred
new-onset mild glossitis after 3 weeks from randomization
and discontinued the study treatment. The mean age of all
patients was 58.7 ± 9.9 years, with mean diabetes’ duration
of 6.5 ± 5.5 years; males represented 70 % of the study
population. Subgroups did not differ for any parameters,
nor for ongoing medications (Tables 1 and 2). At baseline,
92 % of the study population had sub-optimal serum
25(OH)D levels (<75 nmol/L) [38] and 67 % had hypo-
vitaminosis D (<50 nmol/L). Circulating 25(OH)D
concentration significantly increased after oral chole-
calciferol supplementation (Fig. 2), and this goal was
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achieved already after 12 weeks of treatment (Fig. 3);
at 24 weeks, 96 % of active treatment patients reached
sufficient vitamin D balance (≥50 nmol/L) and 71 %
showed optimal 25(OH)D levels (≥75 nmol/L). As ex-
pected, no significant changes in serum 25(OH)D
levels occurred in the placebo group throughout the
study (Fig. 3).
Regarding the primary endpoint, changes in HFF
from baseline to 24 weeks did not differ significantly
between the two study groups (β, 0.63; 95 % CI, –1.6 to
2.8; P = 0.57). Similarly, none of the other hepatic indica-
tors, such as AST, ALT, γ-GT, AST/ALT, CK18-M30,
P3NP and FLI, showed significant changes between the
active treated group and placebo after 24 weeks (Table 3).
Vitamin D supplementation was demonstrated to have a
neutral effect on both metabolic profile and cardiovascular
parameters, as no significant differences between the
groups were found in the indicators of metabolic control
(FBG, HbA1C, lipid profile), insulin resistance (HOMA-
IR, HOMA-β%, QUICKI, FBI, FFAs), body fat distribution
(SAT, VAT, VAT/SAT area), CRP, IMT and FMD. Changes
in ABI at the end of the study differed between treated
and placebo group (β, –0.10; 95 % CI, –0.18 to –0.01;
P = 0.03) but this difference was not significant after
correcting for multiple comparisons (data not shown).
In order to investigate whether vitamin D supplemen-
tation may improve NAFLD exclusively in patients with
hypovitaminosis D at the baseline, we performed an ancil-
lary analysis to compare changes in the primary outcome
from the baseline to 24-week including only patients with
Fig. 1 Trial profile
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basal 25(OH)D <50 nmol/L, but again changes in HFF
were not significantly different between treatment and pla-
cebo group in this subpopulation (β, 2.1; 95 % CI, −0.66 to
4.78, P = 0.13); similar results were found with all other
markers of liver involvement [AST: β, –0.4; 95 % CI, –4.57
to 3.78; P = 0.85; ALT: β, 0.5; 95 % CI, –0.9 to 8.2; P = 0.89;
γ-GT: β, 0.92; 95 % CI, –6 to 7.8, P = 0.79; AST/ALT:
β, 0.02; 95 % CI, –0.08 to 0.11; CK-M30: β, 0.08; 95 %
CI, –87.6 to 150.7, P = 0.59; P3NP: β, 0.25; 95 % CI, –
17.2 to 71,081; P = 0.06; FLI: β, –5.7; 95 % CI, –20.3 to 8.8,
P = 0.42].
Discussion
This is the first randomized, double-blind, placebo-
controlled trial of high-dose vitamin D oral supplemen-
tation performed in T2D patients with NAFLD. This
trial showed that a nutraceutical intervention based on
high-dose vitamin D oral supplementation has no effect
on hepatic fat content in T2D patients affected by
NAFLD – 24-week cholecalciferol supplementation did
not improve either transaminases levels or the serum
levels of biomarkers specific for hepatic injury and fibro-
genesis such as CK18-M30 and P3NP. Similarly, clinical
surrogates of liver impairment in the course of NAFLD,
such as AST/ALT ratio and FLI, did not show significant
changes after vitamin D supplementation. As we specif-
ically aimed to study the effect of vitamin D on fatty
liver in diabetic patients, we also tested the hypothesis of
an involvement of vitamin D in modulating insulin-
resistance, metabolic profile and glycemic control in
these subjects, but none of these parameters significantly
changed after 24-week vitamin D treatment in comparison
with the placebo group. Likewise, vitamin D supplementa-
tion did not induce any specific effect on endothelial
function and subclinical atherosclerosis. Furthermore,
as not all the study participants displayed low circulating
25(OH)D levels at the baseline, we postulated that vitamin
D supplementation could exert favorable effects on
NAFLD only in patients affected by hypovitaminosis D,
but the ancillary analyses did not confirm this hypothesis,
Table 1 Clinical and biochemical characteristics of study
population according to group of treatment
25(OH)D group
baseline (n = 26)
Placebo group
baseline (n = 29)
Age (years) 57.4 ± 10.7 59.8 ± 9.1
Gender (%M) 70 % 60 %
T2D duration (years) 5.9 ± 5.8 6.3 ± 5.4
25(OH)D (nmol/L) 48.15 ± 23.7 40.14 ± 23.9
HFF (%) 7.6 ± 5.7 6.8 ± 5.5
BMI (kg/m2) 29.3 ± 4.4 30.8 ± 4.5
Waist circumference (cm) 100.6 ± 15.2 105.2 ± 12.1
SBP (mmHg) 129.7 ± 16.8 132.2 ± 17.4
DBP (mmHg) 79.2 ± 8.9 82.7 ± 10.7
Total cholesterol (mg/dL) 167.7 ± 37.5 181.6 ± 39.5
HDL-C (mg/dL) 50.3 ± 16.4 49.3 ± 13.2
LDL-C (mg/dL) 93 ± 33.6 105.2 ± 34.5
Triglycerides (mg/dL) 131.5 ± 72.7 133.5 ± 43.8
FBG (mg/dL) 125.3 ± 36.8 135.1 ± 39.9
HbA1c (%/mmol/mol) 6.36 ± 0.9/46 ± 8 6.6 ± 1/48 ± 8
AST (IU/L) 24.12 ± 11.8 23.8 ± 14.6
ALT (IU/L) 31.7 ± 17.1 32.4 ± 26.2
γ-GT (IU/L) 45.3 ± 56.4 35.8 ± 33.3
AST/ALT 0.84 ± 0.3 0.83 ± 0.26
FFAs (μmol/L) 464.6 ± 224.5 519.9 ± 218.4
CK18-M30 (mIU/mL) 212.2 ± 128.2 212.1 ± 155.2
P3NP (pg/mL) 1210.5 ± 1028.6 833.9 ± 955.4
FBI (μU/L) 12 ± 5.1 12.7 ± 5.8
FLI 56.82 ± 26.4 67.7 ± 23.7
HOMA-IR 3.57 ± 1.9 3.87 ± 1.6
HOMA-β% 89.6 ± 63 83.8 ± 63.7
QUICKI 0.33 ± 0.03 0.32 ± 0.02
ADIPO-IR 5.1 ± 3.5 6.3 ± 4.7
CRP (mg/dL) 3.1 ± 3.1 3.6 ± 4.8
Adiponectin (ng/mL) 6.37 ± 3.7 6.4 ± 3.2
VAT area (cm2) 195.9 ± 78.2 191.4 ± 65.9
SAT area (cm2) 229 ± 28.4 258.01 ± 123.9
VAT/SAT ratio 1.07 ± 0.6 1.07 ± 0.62
FMD (%) 5.04 ± 4.5 4.5 ± 3.6
ABI 1.14 ± 0.19 1.1 ± 0.13
IMT (mm) 0.91 ± 0.25 0.87 ± 0.19
Data are presented as mean ± SD, unless indicated otherwise
T2D type 2 diabetes, HFF hepatic fat fraction, BMI body mass index, SBP
systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood
glucose, FBI fasting blood insulin, FLI fatty liver index, CRP C reactive protein,
VAT visceral adipose tissue, SAT subcutaneous adipose tissue, FMD flow-mediated
dilatation, ABI ankle-brachial index, IMT intima-media thickness
Table 2 Ongoing therapies in study population according to
group of treatment
25(OH)D group
baseline (n = 26)
Placebo group
baseline (n = 29)
Insulin treatment (% patients) 16 % 18 %
Number of oral antidiabetic agents
(% patients)
0 11 % 16 %
1 50 % 43 %
2 29 % 30 %
3 10 % 11 %
Statins treatment (% patients) 68 % 57 %
Anti-hypertensive treatment
(% patients)
76 % 75 %
Data are presented as mean ± SD, unless indicated otherwise
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as we observed a similar response in patients with normal
or reduced 25(OH)D at the baseline. Previously, Sharifi et
al. [39] investigated the effect of twice a month 16-week
cholecalciferol supplementation on aminotransferases, in-
sulin resistance and inflammatory profile in non-diabetic
subjects selected on the basis of US-detected fatty liver
and upper-than-normal ALT levels, but no effects were
shown compared to placebo. Notably, a significant de-
crease in the levels of hsCRP and malondialdehyde (a
marker of lipid peroxidation) was found in the subjects
treated with vitamin D. In this study, the intervention was
limited to 4 months and, although the authors aimed to
test a possible effect on insulin resistance, the study was
performed just in non-diabetic patients. Furthermore,
US did not allow performing of a reliable and validated
quantification of hepatic fat content changes before
and after study treatment. Moreover, in a recent study,
high-dose oral vitamin D3 supplementation (25,000 IU/
week) over 24 weeks had no impact on liver histology,
liver biochemistry, insulin resistance or adipocytokine
profile in 12 non-diabetic patients with biopsy-proven
NASH [29].
Our trial has a number of strengths. It is the first study
investigating vitamin D effects on hepatic fat content in
T2D subjects as measured by MRI. In addition, we evalu-
ated serum transaminases, CK18-M30, P3NP, AST/AST
ratio and FLI as possible indicators of hepatic damage in
presence of NAFLD and their changes before and after
24-week cholecalciferol supplementation. The study popu-
lation was recruited in the same diabetes center and,
therefore, all the outcome measurements have been cen-
tralized by definition. Since vitamin D effects on NAFLD
were tested in T2D patients, we evaluated, as secondary
endpoints, the influence of vitamin D treatment on sys-
temic and AT insulin resistance, insulin secretion and gly-
cemic control. Along with the metabolic profile, we were
able to provide a description of the effect of 24-week cho-
lecalciferol treatment on surrogate markers of subclinical
atherosclerosis and endothelial dysfunction, allowing to
extensively investigate the impact of high-dose oral
cholecalciferol supplementation on cardiovascular risk
in patients with both NAFLD and T2D. Furthermore,
96 % of the active-treated group reached vitamin D suf-
ficiency at the end of the study, showing both the
Fig. 2 Comparison between serum 25(OH) D levels in intervention (a) and placebo (b) group. Wilcoxon’s test for paired samples applied
Fig. 3 Serum 25(OH) D levels in intervention versus placebo group. * Independent samples U Mann–Whitney’s test; ^ Multiple dependent
comparisons Friedman’s test
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optimal compliance to study treatment and the ad-
equacy of the cholecalciferol dosage provided.
We are aware that the dimension of this study popula-
tion is not particularly large. However, the final sample
size was greater than the one in the only trial published
so far on non-diabetics with NAFLD [39] and, despite
the relatively high rate of dropouts, was properly powered.
Indeed, at the light of the average HFF < 10 % observed in
patients referring to our Center for clinical evaluations, an
HFF reduction of 50 % was considered as a clinically
relevant goal, allowing to reach a steatosis-free status
in the majority of study participants. In addition, the
Table 3 Comparison of characteristics before and after study treatment in the vitamin D supplementation and placebo groups
25(OH)D group
baseline
25(OH)D group
24-week
Placebo group
baseline
Placebo group
24-week
Adjusted β
(95 % CI)*
P value
25(OH)D (nmol/L) 43.1 (31.1–58.5) 85.8 (73–110) 37.1 (27.3–51.6) 40 (20.8–60.5) 48.6 (35.8 to 61.3) <0.001*
HFF (%) 6.8 (3.9–14.8) 7 (4.4–12.9) 5.9 (3.2–11.2) 5.3 (3.2–9.7) 0.63 (–1.6 to 2.8) 0.57
BMI (kg/m2) 27.9 (27.2–31.8) 27.9 (26.8–31.4) 30.2 (27–33.5) 30.8 (27.6–32.6) 0.05 (–1.3 to 1.4) 0.94
Waist circumference (cm) 99 (92–106) 94.2 (99.5–107.6) 105 (95–110) 105 (96.5–109) 0.86 (–2.8 to 4.5) 0.64
SBP (mmHg) 130 (120–140) 130 (120–140) 130 (120–140) 130 (120–150) –2.6 (–12.3 to 6.9) 0.58
DBP (mmHg) 80 (70–90) 80 (75–90) 80 (75–90) 80 (80–90) –1.38 (–6.8 to 4) 0.61
Total cholesterol
(mg/dL)
176 (147–195) 168.5 (144–194) 179 (150–209) 162 (146–194) –5.7 (–22.3 to 10.8) 0.49
HDL-C (mg/dL) 50 (34–59) 48 (42–54) 47.5 (40.2–54) 49 (41–61) –0.46 (–5.1 to 4.2) 0.84
LDL-C (mg/dL) 92 (63–116) 88 (65.5–103.7) 94.3 (78–129) 85 (73–105) –4.6 (–19.5 to 10.3) 0.53
Triglycerides (mg/dL) 100 (65–181) 116.5 (87–176) 128.5 (104.5–164) 116 (91.5–154.2) –0.24 (–42.5 to 42) 0.99
FBG (mg/dL) 126 (103–148) 115 (102.114) 124 (107.5–154) 127 (105–160) 2.5 (–18.9 to 23.9) 0.48
HbA1c (%/mmol/mol) 6.3 (5.9–6.7)/45(41–50) 6 (5.6–6.9)/42 (38–52) 6.5 (6–7.2)/48(38–55) 6.4 (6–7.3)/46 (38–56) –0.05 (–0.42 to 0.33) 0.80
AST (IU/L) 20 (17–30) 20.5 (16–25.7) 20.5 (16–27) 22 (17–30) –2.4 (–5.7 to 0.79) 0.13
ALT (IU/L) 26 (18–48) 29 (20–37.5) 27 (19.5–40) 28.5 (21–40) –4.6 (–11.9 to 2.5) 0.20
γ-GT (IU/L) 29 (19–53) 28 (19.5–43) 22.5 (16–39) 23 (17–40.5) –0.95 (–6.1 to 4.2) 0.71
AST/ALT 0.83 (0.62–1) 0.8 (0.6–1) 0.77 (0.67–0.92) 0.72 (0.61–0.92) 0.02 (–0.11 to 0.06) 0.60
CK18-M30 (mIU/mL) 186.7 (139–240.4) 170.3 (102.1–271.9) 212.6 (66–315.9) 130.3 (85–234.6) 0.08 (–63 to 114.7) 0.56
P3NP (pg/mL) 1334.9 (166.8–1981) 1229.5 (327.6–1924) 464.6 (66.4–1270.9) 390.1 (116.2–1290) 0.19 (–23.7 to 738.4) 0.07
FFAs (μmol/L) 13.6 (8.8–19.7) 6.5 (4.2–8) 14.1 (8.9–19.7) 4.9 (3.2–8.1) 21 (–10.8 to 15) 0.75
FBI (μU/L) 11.7 (7.4–15.8) 11.5 (8.8–17.2) 13 (8.3–16) 13.1 (9.5–19) –1.2 (–3.7 to 1.3) 0.35
FLI 68.6 (33–83.2) 54.5 (35.5–79.8) 79.8 (50.2–89) 70.5 (57–84.3) –5.3 (–15.9 to 5.3) 0.32
HOMA-IR 3.9 (1.9–5.9) 3.4 (1.9–5.6) 4 (2.5–5.5) 4 (2.8–6.1) 0.01 (–1.3 to 1.3) 0.98
HOMA-β% 71.3 (50.3–114.8) 68 (51.8–97.5) 67.3 (42–126.3) 71 (50–116) –18.7 (–49.1 to 11.7) 0.22
QUICKI 0.31 (0.3–0.34) 0.32 (0.3–0-34) 0.31 (0.3–0.33) 0.31 (0.29–0.33) 0.005 (–0.008 to 0.018) 0.40
ADIPO-IR 5.4 (2.5–9.5) 2.4 (1.3–3.7) 5.7 (2.8–7.9) 2.8 (1.5–4.3) 0.013 (–1.66 to 1.68) 0.98
CRP (mg/dL) 3 (0.25–6.6) 0.8 (0.15–1.6) 1.3 (0.6–4) 0.5 (0.1–3.5) –0.04 (–1.6 to 1.5) 0.96
Adiponectin (ng/mL) 5.3 (3.3–9.6) 12.7 (9.9–22.8) 5.7 (3.9–8.9) 12.2 (9.5–16.4) 5.2 (–3.57 to 14) 0.24
VAT area (cm2) 173.4 (138.5–251) 183 (130–322) 190 (127.3–238) 188.7 (125–265.4) 6.1 (–45.9 to 58.1) 0.81
SAT area (cm2) 195.7 (132.5–340) 210.7 (115–366) 222.6 (169–371) 249.2 (188–392) –21.9 (–74.07 to 30.08) 0.4
VAT/SAT ratio 0.93 (0.48–1.6) 0.93 (0.59–1.5) 0.81 (0.52–1.2) 0.89 (0.39–1.2) 0.08 (–0.18 to 0.28) 0.54
FMD (%) 2.9 (0.7–8.1) 2.5 (0.9–4.7) 4.4 (2.1–6.4) 4.3 (1.7–6.2) –1.8 (–4.6 to 1.02) 0.20
ABI 1.1 (1–1.2) 1.04 (0.9–1.1) 1.13 (1–1.2) 1.1 (1–1.1) –0.10 (–0.18 to –0.01) 0.03*
IMT (mm) 0.8 (0.72–0.95) 0.81 (0.7–1) 0.8 (0.74–1) 0.84 (0.7–1) –0.04 (–0.14 to 0.04) 0.33
Data are presented as median (25°–75° percentile), unless indicated otherwise, significance between groups was assessed by linear regression analysis adjusted
for the baseline value
*Statistically significant
T2D type 2 diabetes, HFF hepatic fat fraction, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose,
FBI fasting blood insulin, FLI fatty liver index, CRP C reactive protein, VAT visceral adipose tissue, SAT subcutaneous adipose tissue, FMD flow-mediated dilatation,
ABI ankle-brachial index, IMT intima-media thickness
Barchetta et al. BMC Medicine  (2016) 14:92 Page 8 of 10
study population has been extensively phenotyped and
well matched for all the features of NAFLD, diabetes
and metabolic syndrome.
One limitation of our study is the lack of liver biopsies,
which did not allow us to evaluate histological changes
in our cohort. However, as our population exhibited
relatively mild hepatic disease, the surrogate endpoints
assessed by MRI, along with the measurement of serum
CK-18 and P3NP levels as validated biomarkers of hep-
atic damage and fibrogenesis in the course of NAFLD
[26, 27, 31], can be considered suitable for this phase of
the study.
Despite some studies demonstrating the association
between hypovitaminosis D and NAFLD/NASH [18–20]
and the direct effect of vitamin D in modulating hepatic
inflammation, fibrosis and insulin-resistance both in vivo
and in vitro [22–25, 28], very recently, the existence of
an independent relationship between biopsy-proven
NASH and circulating low 25(OH)D levels has been
confuted by two independent studies performed in sub-
jects with different metabolic phenotypes [40, 41].
Although the active treated group almost doubled the
mean 25(OH)D levels after just 12-week supplementation,
our study did not meet the primary endpoint of showing a
reduction of hepatic fat content in NAFLD patients under-
going 24-week high-dose oral cholecalciferol supplemen-
tation. Indeed, it is possible to speculate that either the
period of exposure to normal-optimal 25(OH)D con-
centration was not enough for modifying the hepatic
fat content and the clinical/biochemical indicators of
hepatic involvement in NAFLD, or the link between
vitamin D and NAFLD could be appreciated only in
specific sub-populations of patients with fatty liver. As
we aimed specifically to assess the efficacy of vitamin D
supplementation on liver steatosis in T2D patients, the
study population was selected among T2D patients re-
ferring to our Diabetes outpatients’ clinic for routine
diabetes care. Likewise, this setting led to recruitment
of subjects with milder NAFLD levels than those de-
tectable in patients purposely referring to Hepatology
clinics for the treatment of liver diseases. Indeed, we
cannot rule out that a certain effect of oral vitamin D
may be appreciated in patients with more severe NAFLD
and NASH. Considering the overall strong rationale be-
hind the favorable cost/benefit ratio and the safety of oral
vitamin D supplementation, further randomized con-
trolled studies, with a longer period of intervention and
performed in different populations, are warranted before
definitively excluding a role of vitamin D in NAFLD
treatment.
On the other hand, it is also plausible to hypothesize
that, despite hypovitaminosis D representing an inde-
pendent risk factor for NAFLD, once this condition is
established, late vitamin D supplementation may not be
capable of reverting the negative effects of its prolonged
deficiency on liver parenchyma. Therefore, strategies
preventing hypovitaminosis D in the general population
and, in particular, in dysmetabolic patients at increased
risk of NAFLD could result in better outcomes than
intervention studies performed after NAFLD diagnosis.
Conclusions
This study demonstrated for the first time that a nutra-
ceutical intervention based on 24-week oral vitamin D
supplementation did not improve hepatic steatosis or
metabolic/cardiovascular parameters in T2D patients with
NAFLD. Hepatic steatosis still remains a widespread con-
dition without an appropriate therapy. Studies with longer
intervention periods, even in subjects at high risk of
NAFLD, are warranted for exploring the effect of long
time exposure to vitamin D.
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